JPM: Glaxo's cancer unit, in commercial 'building mode,' gets choosy with M&A

17th January 2020 Uncategorised 0

SAN FRANCISCO—It was one year ago that GlaxoSmithKline nabbed Tesaro, bringing on Zejula. But don’t expect it to spring for more commercial-stage oncology products anytime soon. While “we are not excluding the opportunity” for products on the market, it “has to be a good fit for the situation,” said Axel Hoos, SVP of Oncology R&D.

More: JPM: Glaxo's cancer unit, in commercial 'building mode,' gets choosy with M&A
Source: fierce